Objective: The classification of endometrial cancer, based on histology, provides important prognostic information and is pivotal for assessing appropriate surgical and adjuvant therapy. However, molecular determinants could be incorporated to improve the current classification system. Materials and Methods: In our study,Seventy patients diagnosed with endometrial cancer between 2016 and 2021 were included. Pathological type, stage at diagnosis, the date of initiation of treatment, survival information, and molecular characteristics of the patients were recorded.The chi-square test was used to analyze categorical variables.Independent groups were compared using an independent sample t-test and Mann-Whitney-U test. Overall survival was estimated using the Kaplan-Meier method, and results were compared using the log-rank test. The independent prognostic risk factors were analyzed using the Cox regression model. Results: The primary findings obtained were as follows: (1) Median overall survival in de novo metastatic cases was significantly lower than that in patients with subsequent relapse; (2) The most common endometrioid type was observed based on the histopathological examination results. The undifferentiated endometrial cancer subtype demonstrated a highly aggressive course; (3) In the present study, p16 was positive at a significantly higher rate over 60 years of age (p = 0.027). Conclusion: Various prognostic factors were examined in this study. Molecular markers may have an important role in determining the prognosis of endometrial cancer. The positivity of molecular markers such as p16 may contribute to mortality, especially in the geriatric age group.